Trial Profile
A Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients With Stage III and IV Squamous Cell Carcinoma of the Head and Neck.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Nasopharyngeal cancer; Oropharyngeal cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 07 Jun 2016 Results of an exploratory analysis assessing racial disparity in oncologic and patient-reported quality of life presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 17 Jul 2012 Planned end date changed from 1 Jan 2013 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 17 Jul 2012 Planned end date changed from 1 Jan 2013 to 1 Mar 2012 as reported by ClinicalTrials.gov.